- ECONOMIC IMPACT -

Latest update: 15 September 

The global economy is forecasted to return to pre-crisis levels by the end of 2021 or early 2022. 

According to Statistics South Africa, real GDP in the nation expanded by 1.2% in Q2 2021.

6.2%

The unemployment rate in OECD nations stood at 6.2% in July 2021, down from 6.4% in June 2021.

4.5%

World economic growth is projected at 5.7% in 2021 and at 4.5% in 2022, according to HIS Markit.

Impact of Covid-19 on equity indices

- SECTOR IMPACT: PHARMA -

Latest update: 03 September

industry development

5,746

Currently, there are 5,746 clinical trials for Covid-19 and promising clinical data continues to emerge for Covid-19 vaccines. 

1,052

Trial disruption is levelling off, with 1,052 trials still disrupted and 627 pharma/biotech companies and clinical research organisations associated with disrupted trials.

Vaccination developments

With multiple vaccines having shown impressive efficacy, notably for reductions in the need for hospitalisation and mortality, the window for utility for Covid-19 therapies may be rapidly contracting.


However, this may be offset increased illness caused by the rise of vaccine-resistant variants and shortages of vaccines in certain countries, such as India.


Low vaccination rates in localised areas could lead to ‘hyperlocal outbreaks’ where communities surrounded by high vaccination areas could experience outbreaks in localised clusters. 

Key pharma market developments

Share this article

Go to article: Home | Unpacking innovation in biologics Go to article: In this issueGo to article: ContentsGo to article: MyonexGo to article: Controlant Company InsightGo to article: ControlantGo to article: SHL MedicalGo to article: LabcorpGo to article: ReutersGo to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: Covid-19 executive briefing by GlobalDataGo to article: Mimotopes Company Insight Go to article: MimotopesGo to article: TQS Integration Company InsightGo to article: TQS IntergrationGo to article: Biesterfeld Go to article: CommentGo to article: Biotech and China: a global opportunityGo to article: Intranasal ketamine could effectively treat phantom painGo to article: EU biosimilar wave slows as biosimilar approvals decrease in the EUGo to article: Biosynth Carbosynth Company InsightGo to article: Biosynth CarbosynthGo to article:  Molnár-Institute Company Insight Go to article: Molnar-InstituteGo to article: SkyepharmaGo to article: In DepthGo to article: Unpacking the complex challenge of biologicsGo to article: Living medicines: using bacteria to fight cancerGo to article: The marred history of HIV vaccine trialsGo to article: Has Covid-19 exposed the weakness of the US pharma supply chain?Go to article: How the pandemic pushed pharmacovigilance to innovateGo to article: ExeVir: the llama-derived antibody that could fight Covid-19Go to article: BEA TechnologiesGo to article: WatlowGo to article: DuojectGo to article: ButterworthGo to article: In DataGo to article: Data: Big Data hiring efforts in pharmaGo to article: The pharma industry key listGo to article: Global markets and indicesGo to article: Macro-economic indicatorsGo to article: Macro-economic indicators (page 2)Go to article: EventsGo to article: Next issue